atg7

ATG7-IN-1 is a selective ATG7 inhibitor with an IC50 of 62 nM.

ATG7-IN-2 (compound 1) is a highly potent ATG7 protein inhibitor with an IC50 of 0.089 μM, effectively suppressing autophagy marker LC3B activity and regulating the autophagy process [1].

ATG7-IN-3 (compound 18) is an effective ATG7 inhibitor with an IC50 value of 0.048 μM, exhibiting inhibitory actions on autophagy and effectively hampering the development of endogenous LC3B puncta in the H4 neuroglioma cell line [1].

Antitumor agent-192 (Compound 2f) is a β-carboline antitumor compound. It induces autophagy in HCT116 cells via the ATG5 ATG7 pathway. The IC50 of Antitumor agent-192 against human tumor cell lines is below 5 μM, and it significantly inhibits tumor growth and reduces tumor weight in xenograft mouse models of colorectal cancer.

Antitumor agent-199 (Compound 4b) is an antitumor compound exhibiting significant antiproliferative activity against various tumor cell lines. It can induce autophagy (autophagy) in cancer cells through the ATG5/ATG7 pathway, making it useful for tumor research.

Chromomycin A2 is an aureolic acid that has been found in several marine actinomycetes and has antibacterial and anticancer activities. Chromomycin A2 inhibits the growth of B. subtilis in an agar diffusion assay. It also inhibits the growth of human SGC7901 gastric cancer, HepG2 hepatocellular carcinoma, A549 lung epithelial adenocarcinoma, HCT116 colon cancer, and COC1 ovarian cancer cells, as well as human umbilical vein endothelial cells (HUVECs; IC50s = 4, 0.5, 3, 5, 5, and 8 nM, respectively). Chromomycin A2 (30 nM) halts the cell cycle in the G0 G1 phase and increases the protein levels of LC3A and LC3B in MALME-3M melanoma cells, indicating that it induces autophagy. It also increases the levels and promoter activity of the autophagic proteins ATG7 and ATG10 and reduces cell viability to 50% in human SCC-11 squamous cell carcinoma cells when used at a concentration of 30 nM.

Antitumor Agent-82 is a potent anti-tumor compound that exhibits anti-proliferative activity and induces cell autophagy through the ATG5 ATG7 signaling pathway.

CPTH6, a thiazole derivative, selectively inhibits the lysine acetyltransferase activity of Gcn5 and pCAF without affecting p300 or CBP. It effectively blocks the acetylation of H3/H4 histones and α-tubulin in various leukemia cell lines, leading to reduced cell viability by arresting the cell cycle in the G0/G1 phase and inducing apoptosis. Additionally, CPTH6 disrupts autophagy across several tumor cell lines, primarily by interfering with ATG7-mediated autophagosomal membrane elongation.